Fluorouracil Injection

29 January 2008

Products Affected - Description

Fluorouracil 50 mg/mL, Valeant

Reason for the Shortage

• Valeant states the shortage is due to a raw materials issue.

Estimated Resupply Dates

• Fluorouracil injection is on back order with no release date from Valeant Pharmaceuticals International.
• Teva-Sicor, APP Pharmaceuticals (formerly Abraxis Pharmaceutical Products), and Generamedix have all products available.

Related Shortages

• Bleomycin Injection
• Carmustine Injection— Resolved
• Cisplatin Injection— Resolved
• Cyclophosphamide for Injection— Resolved
• Cyclophosphamide Tablets— Resolved
• Cytarabine Injection
• Doxorubicin Injection— Resolved
• Epirubicin Injection— Resolved
• Hydroxyurea Capsules— Resolved
• Ifosfamide— Resolved
• Interferon Alfa Injection— No Longer Available
• Leuprolide Implant— No Longer Available
• Mechlorethamine Hydrochloride Injection— Resolved
• Melphalan Injection Injection— Resolved
• Methotrexate Injection
• Mitomycin Injection
• Paclitaxel Injection— Resolved
• Procarbazine Capsules— Resolved
• Thiotepa Injection
• Vinblastine Injection
• Vincristine Injection— Resolved

Updated

January 29, 2008; November 28, 2007; October 3, 2007; September 21, 2007; September 4, 2007; July 3, 2007; May 4, 2007; April 3, 2007; February 6, 2007; October 3, 2006; September 19, 2006; August 4, 2006; June 13, 2006; May 11, 2006; University of Utah, Drug Information Service

Back to Drug Shortage Product Bulletins